Catalyst Pharmaceutical Partners

Catalyst Pharma's Firdapse bet on congenital myasthenic syndromes turns sour
Catalyst Pharma's Firdapse bet on congenital myasthenic syndromes turns sour
Endpoints
Catalyst Pharmaceutical Partners
FDA
Firdapse
cogenital myasthenic syndromes
Flag link:
Catalyst dives as FDA approves rival's rare disease drug
Catalyst dives as FDA approves rival's rare disease drug
Biopharma Dive
FDA
Catalyst Pharmaceutical Partners
Jacobus Pharmaceuticals
Ruzurgi
Firdapse
LEMS
Flag link:
Catalyst Pharma says autoimmune disorder drug safe for heart
Catalyst Pharma says autoimmune disorder drug safe for heart
Reuters
Catalyst Pharmaceutical Partners
Lambert-Eaton myasthenic syndrome
Firdapse
Flag link:
6 Charts Explain An Ugly October for Biotech Stocks
6 Charts Explain An Ugly October for Biotech Stocks
TheStreet.com
biotech
Catalyst Pharmaceutical Partners
Acadia
Celldex
Biocryst
Flag link:
Catalyst Pharmaceuticals And Their Business Plan
Catalyst Pharmaceuticals And Their Business Plan
Seeking Alpha
Catalyst Pharmaceutical Partners
Biomarin
Biogen Idec
Firdapse
Lambert-Eaton myasthenic syndrome
Flag link:
Tiny Catalyst soars after rare disease drug scores 'breakthrough' at FDA
Tiny Catalyst soars after rare disease drug scores 'breakthrough' at FDA
Fierce Biotech
Catalyst Pharmaceutical Partners
Firdapse
Biomarin
FDA
breakthrough therapies
Lambert-Eaton myasthenic syndrome
Flag link:
Is There Any Substance To The Buyout Rumors Surrounding BioMarin And Catalyst?
Is There Any Substance To The Buyout Rumors Surrounding BioMarin And Catalyst?
Seeking Alpha
M&A
Biomarin
Catalyst Pharmaceutical Partners
Flag link:
These 4 'High-Potential' Biotech Stocks Could Outperform In 2013
These 4 'High-Potential' Biotech Stocks Could Outperform In 2013
Seeking Alpha
Arena Pharmaceuticals
Gilead
Biomarin
Acadia
Catalyst Pharmaceutical Partners
Flag link:
Catalyst Pharmaceutical And Dynavax Are Buys Now
Catalyst Pharmaceutical And Dynavax Are Buys Now
Seeking Alpha
Catalyst Pharmaceutical Partners
Dynavax
Flag link:
This Week in Biotech: Part 2
This Week in Biotech: Part 2
Motley Fool
Biocryst
Catalyst Pharmaceutical Partners
Pluristem Therapeutics
Vivus
Arena Pharmaceuticals
Eisai
Flag link:
Savient Pharmaceuticals May Continue To Run Higher
Savient Pharmaceuticals May Continue To Run Higher
Seeking Alpha
Savient
StemCells
Sarepta
Catalyst Pharmaceutical Partners
Hemispherx Biopharma
Flag link:
Lessons From Biotech's Best Third Quarter Stocks
Lessons From Biotech's Best Third Quarter Stocks
TheStreet.com
Celsion
XenoPort
Peregrine Pharmaceuticals
Sunesis
Opexa
StemCells
Catalyst Pharmaceutical Partners
Hemispherx
Sarepta
Savient
Flag link:
Buying Into Catalyst Pharma's Fast Tracked Vigabatrim On Friday
Buying Into Catalyst Pharma's Fast Tracked Vigabatrim On Friday
Seeking Alpha
Catalyst Pharmaceutical Partners
Vigabatrin
CPP-109
cocaine addiction
Flag link:
3 Companies With Exciting Phase II Trial Data Close Out 2012
3 Companies With Exciting Phase II Trial Data Close Out 2012
Seeking Alpha
Peregrine Pharmaceuticals
bavituximab
Vigabatrin
Catalyst Pharmaceutical Partners
OncoSec
NeoPulse
Flag link:
Merck Suffers Same Flaw As Facebook
Merck Suffers Same Flaw As Facebook
Seeking Alpha
Merck
Facebook
Ampio Pharmaceuticals
Catalyst Pharmaceutical Partners
Flag link: